Instil Bio Inc Dossier - Source-backed chat

Instil Bio Inc

TILNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.61

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $7.24Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $49.1M

Enterprise Value $128.3M

Shares Outstanding 6.9M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Instil Bio, Inc. is in a transitional, pre-revenue phase following a series of major strategic shifts. In January 2026, the company discontinued the clinical development of its former lead bispecific antibody candidate, AXN-2510, and terminated its license agreement with ImmuneOnco. This followed the previous suspension of its legacy tumor-infiltrating lymphocyte (TIL) therapy programs (including ITIL-306). Currently, the company is operating as a lean, low-overhead vehicle actively evaluating potential acquisitions and in-licensing opportunities to rebuild its pipeline. Backed by a solid cash position of $74.7 million as of March 31, 2026, which management expects will fund operations beyond 2027, the stock trades near its cash value. While the downside is protected by this cash cushion, the lack of active clinical-stage assets in the US and the uncertainty surrounding future acquisitions justify a Hold recommendation until a clear strategic transaction is finalized.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.00

Mean target$7.00

High · most bullish analyst$7.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.5015%

The company fails to secure attractive assets or overpays for a high-risk, early-stage candidate that faces clinical or regulatory setbacks. Continued administrative cash burn gradually erodes the cash balance, and the lack of clinical progress leads to persistent undervaluation relative to historical cash levels.

Base CaseCentral scenario

$8.5060%

The company remains pre-revenue while actively searching for high-quality clinical assets to in-license or acquire. R&D and G&A expenses remain tightly controlled, preserving the cash runway beyond 2027. The stock trades in a range close to its net cash value, with limited near-term volatility until a definitive transaction is announced.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong balance sheet with $74.7 million in cash and marketable securities as of March 31, 2026, providing a runway beyond 2027.
Significantly reduced operating cash burn following aggressive restructuring, including the closure of legacy manufacturing facilities.
Flexibility to act as a clean 'blank check' biotech vehicle to acquire distressed or undervalued clinical-stage assets.

Key Investment Risks

No active clinical-stage pipeline assets currently under direct development in the US following the discontinuation of AXN-2510 in January 2026.
High dependency on successful execution of future M&A or in-licensing transactions to generate long-term shareholder value.
Inherent clinical, regulatory, and manufacturing risks associated with any newly acquired biotechnology candidates.

Thesis Invalidation Triggers

Announcement of an acquisition or in-licensing deal that significantly depletes cash reserves without clear clinical validation.
Substantial increase in quarterly G&A cash burn that shortens the projected runway to under 18 months.
Inability to secure any viable therapeutic candidates within the next 12 to 18 months, leading to a slow liquidation scenario.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.